Bryan Johnson

Bryan Johnson is an American entrepreneur who moved from payments and deep-tech investing into a public, data-driven longevity experiment. His earlier identity is anchored in Braintree/Venmo, OS Fund, and Kernel: OS Fund says he invested $100M into OS Fund in 2014, founded Kernel in 2016 with another $100M commitment, and previously founded Braintree, sold to PayPal in 2013 for $800M. The University of Chicago profile frames this as a post-Braintree pivot from commerce infrastructure toward “help humanity thrive” ventures in engineered biology, climate/health deep tech, and brain interfaces.

Since 2021, Johnson’s public center of gravity has been project blueprint, a self-experiment intended to measure 70+ organs, quantify biological age, and use an evidence-and-biomarker feedback loop to choose interventions. In the original Project Blueprint post, Johnson described “firing Evening Bryan” from food decisions, shifting decision authority from preference to biomarkers, and treating Blueprint as a “stock ticker” for the current state of anti-aging science, albeit explicitly as an N=1 experiment.

Johnson’s worldview now fuses personal health optimization with the broader dont die frame: death, biological aging, planetary risk, and AI-era existential risk are treated as problems for coordinated measurement, technology, community, and norm formation. His home page presents three pillars: Don’t Die as community, Protocol as freely available information, and Blueprint as interventions/commerce.

Key entities and relationships

• project blueprint — Johnson’s protocol, self-experiment, product ecosystem, and measurement methodology.
• dont die — the community/ideology that generalizes his health project into a civilizational slogan.
• Kernel — neurotechnology company founded by Johnson; relevant to his recurring “what we measure, we improve” thesis.
• OS Fund — deep-tech fund founded/co-founded by Johnson; part of his post-Braintree capital allocation thesis.
• Braintree/Venmo — the payments company/acquisition that funded later projects.

Recurring claims in Johnson’s own materials

Johnson claims to be among the most biologically measured people, and his protocol page lists percentile-style outcomes across muscle, fat, bone mineral density, resting heart rate, fertility, blood pressure, vascular function, sleep, grip strength, glucose, and blood-sugar control. These are primary-source self-reports and should be treated as claims requiring context rather than independent clinical validation.

On X/Twitter in May 2026, Johnson’s messaging emphasized sleep, resting heart rate before bed, biomarkers-in-context, sauna experiments, peptide experiments, certified products, and scaling a “female Bryan Johnson” / female-specific protocol via Kate Tolo. This shows that the public project is no longer just a static protocol; it is a daily media feed of experiments, product launches, health claims, and “Don’t Die” norm-setting.

On May 23–24, 2026, Johnson also used X/Twitter to frame his Enhanced Games commentary role as “Human Enhancement Expert”: he highlighted athlete measurement, claimed medical supervision and optional enhancement, and tied performance-enhancing protocols to the same measurement-first posture that runs through biomarker driven longevity protocols. The posts are useful evidence for his public positioning, but not independent validation of Enhanced Games safety or efficacy.

In June 2026, Johnson’s feed added two durable dashboard themes. First, he announced a prescription-therapeutics layer at medicine.immortals.com, describing Tadalafil/Cialis, Metformin, Oral Minoxidil, Tretinoin, Estradiol, and Acarbose as prescriptions he personally uses via licensed doctors and pharmacies. Second, he highlighted daily 5 mg Tadalafil/Cialis as a blood-flow/longevity intervention while explicitly caveating that the cited outcome data are observational associations, not proof of causation or medical advice. Treat both as Johnson/Blueprint commercial and protocol claims, not clinical recommendations.

The same June batch continued everyday protocol storytelling: quantified jet-lag recovery claims, sleep-as-recovery messaging, and a vegetable/legume-heavy breakfast example. Those posts are useful for showing how Blueprint blends measurement, routine snapshots, and product expansion, but they should stay in the claim/context lane rather than being rendered as personal health instructions.

On June 16–17, Johnson added a tighter methodological arc: a sauna/HSP27 self-experiment using ingestible core-temperature tracking, repeated blood draws, and a later heart-rate trace; then a Nature-feature thread with a formal Blueprint/Immortals essay arguing that RCTs are necessary but not sufficient for individualized longevity optimization. The public-site stance is to surface the measurement method and mainstream-attention signal while preserving Johnson’s own caveat that the listed first-in-human biological observations need further validation.

On June 21, Johnson’s feed turned from biomarker claims to media and fatherhood positioning. A reply to Ezra Klein and Gary Shteyngart pushed back on being framed as “modern dystopia” and re-articulated Don’t Die as a rejection of YOLO-style acceptance of self-destructive habits. Two other posts described parenting mental models and a childhood exercise in giving away water and bars without reward, using overjustification effect and moral elevation language. These are public-persona and ideology signals, not health-protocol evidence.

On June 22, the feed returned to commercial health infrastructure: Johnson announced that Immortals Rx had expanded into “microdose” GLP-1s, peptides, and NAD+, listing semaglutide/Wegovy, tirzepatide/Zepbound, SGLT2 inhibitors, peptide complexes, glutathione, and NAD+ alongside the earlier tadalafil/metformin/minoxidil/tretinoin/acarbose stack. The same batch included a fermented-foods post citing an unnamed randomized trial, a biological-age joke, and an N=1 meibomian-gland dry-eye procedure report. The Rx expansion is dashboard-level business/protocol news; the food and procedure posts remain attributed claims or self-reports, not medical advice.

On June 23, Johnson used a long endorsement of the third-party “Midjourney scanner” to state a clearer measurement model: blood draws for chemical state, wearables for function, and imaging for structural state, with baseline + longitudinal tracking as the real unlock. The same batch added a public exchange with Nassim Nicholas Taleb about attribution/confounding, a personal “one international trip per quarter” travel cap derived from China/India/Australia biomarker recovery, and a detailed preview of Kate Tolo’s cycle-anchored daily measurement routine for the female protocol. These are useful signals about Johnson’s measurement worldview and public reception, but the scanner, travel rule, and female-protocol readouts remain attributed claims or exploratory protocol design rather than clinical advice.

On June 24, Johnson published two durable posts. The first was his clearest structured immortality manifesto, defining immortality as life expectancy outpacing aging and arguing from biology, AI capability, and Johnson-reported AI-assisted cancer anecdotes before introducing the “Die Economy” versus “Don’t Die Economy” frame for Immortals. The second defended consumer wearables as relative-tracking tools despite divergent absolute readings across brands. Together they sharpen the split between Johnson’s low-confidence future ideology and his medium-confidence measurement methodology; neither should be read as personal medical advice or independent validation of the claims.

On June 25, Johnson’s most substantive new post was a self-reported inherited-cancer screen: a combined DNA + RNA panel across 71 genes, with a negative result. He framed it as early risk stratification for surveillance rather than a cancer diagnosis. The same batch repeated his sleep-as-longevity-drug checklist and amplified New York Post coverage of Kate Tolo’s skin-age biohacking; those are recurring sleep/female-protocol signals, while the cancer panel is the novel measurement addition.

On June 26, Johnson followed that cancer-risk theme with a single biological-age post. He cited an unnamed study claiming that people whose biological age runs ahead of chronological age have higher early-cancer risk under 55, with the widest gaps associated with higher lung, uterine, and gastrointestinal cancer risk. The post is useful as a bridge between his biological-age-clock messaging and cancer-surveillance frame, but remains a tweet-level lay citation rather than independently verified medical guidance.

On June 27, Johnson’s feed shifted from biomarker claims to cultural reception. He quote-tweeted a TBPN video claiming French cigarette packs had reappropriated his image and Don’t Die slogan, then joked about being “the face of French cigarettes” while nudging smokers toward sleep. Because the underlying claim is third-party and unverified, the dashboard records it only as a meme/brand-reception signal. A second post that day urged care for self, others, the planet, animals, and life; it restates the Don’t Die worldview without adding a new protocol or medical claim.

On June 28, Johnson used a Charlie Munger psychology-of-misjudgment thread to explain why “smart people” neglect health: delayed incentives, slow decline, consistency pressure, denial, and avoiding tests to avoid bad news. This is useful public-persona context because it shows Johnson translating Don’t Die into behavioral economics language, but it remains attributed framing rather than clinical evidence or a new protocol.

On June 29–30, Johnson moved briefly outside the health stack into AI-governance speculation. One high-reply post asked, “Who would you trust to run the world?” and a longer essay argued that “rights follow from relative competence,” so adult rights could be curtailed if AI proves better at driving, law, medicine, finance, governance, and similar domains. He explicitly hedged that he was not advocating the future or calling it inevitable. The dashboard treats this as a low-confidence opinion signal about Johnson’s broader future-of-humanity reasoning, not as a Blueprint, biomarker, or medical claim.

Later on June 30, Johnson returned to health with one of his most substantive personal disclosures: he said he had been formally diagnosed with autoimmune gastritis after years of low ferritin that did not progress to anemia and therefore was easy for prior care teams to dismiss. His account says the diagnosis came through anti-parietal-cell antibody bloodwork, a bi-directional endoscopy, and five stomach biopsies, after an overhauled medical team revisited the unresolved iron-storage signal. The same post named Immortals Care as a “$1M a year protocol” and sketched a four-tier autoimmune-gastritis roadmap, from current support/monitoring to explicitly investigational JAK/STAT, IL-17, regulatory-T-cell, CAAR-T, and AI-designed-antibody ideas. Treat this as Johnson’s self-reported diagnosis and research agenda; the advanced tiers are not approved cures or reader advice. The same daily batch also included a longevity ↔ AI-compute investment disclosure in Etched, which he framed as infrastructure for drug-discovery search, and a Kate Tolo / WSJ media-reach update for the female-health protocol.

On July 3, Johnson continued the AIG story with a diagnostic follow-through thread: he said he is sequencing 1,000,000 individual immune cells to identify the autoreactive “rogue” clones attacking his stomach lining. Replies quantified the draw as 198.5 mL, 33 tubes, 50 tests, roughly 100 biomarkers, and the 1M-cell decode, and reported he was “no longer iron deficient” after a 1,000 mg Monoferric infusion. A longer follow-up pushed back on meat/sunlight/food “cure” suggestions, arguing low ferritin is downstream of parietal-cell destruction and that targeted therapy requires identifying the immune-cell clone/receptor pattern first. Treat the sequencing as Johnson’s self-reported measurement modality and diagnostic reasoning, not an established AIG cure or reader testing advice.

Reading stance

Use Johnson as a high-signal case study in biomarker driven longevity protocols, but keep claims separated into: (1) independently verifiable biography/business facts, (2) Johnson/Blueprint primary-source health claims, and (3) third-party scientific/medical interpretation. His transparency and measurement density are useful; the N=1 design, simultaneous intervention changes, commercial incentives, and reliance on surrogate biomarkers limit generalizability.